Our patients, families, and caregivers have been asking us for more ways to learn about rare blood cancers and bone marrow failure diseases. So, we're coming to you today, thanks to generous support from individual donors and our corporate partners, including Celgene.
Dr Vu Duong explains risk classifications for MDS. He dives into IPSS and IPSS-R scores, focused on helping patients to understand the meanings of high-risk and low-risk MDS.
Julie Lowe, AAMDSIF Director for Strategic Initiatives, anticipates your questions about getting involved with the Aplastic Anemia and MDS International Foundation in this recent interview.
Dr. Tiffany Tanaka from the University of California, San Diego explains the development of High-Risk MDS into AML. She talks about new diagnostic and treatment regimens for these patients.
Dr. Ehab Atallah discusses the good news about treatment for MDS, Myelodysplastic Syndromes, for patients ages 65 and older.
Terri shares the journey of Thomas' surprise diagnosis, rigorous treatment, and wonderful survivorship in this conversation.
Why would I choose a clinical trial? What kind of additional care would I receive? How do I know if I qualify?
Christina Cline, RN, BSN, CCRC, explains both patient and nurse navigator roles in this recent recording.